Trending...
- Single Operated Newsletter - Create A Podcast Using Artificial Intelligence
- California: Governor Newsom Statement on August Jobs Report 9.17.21
- Black-Owned Fitness Start-Up Aims to Fix Healthcare for African Americans
PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
- Jefferies Virtual Healthcare Conference on Thursday, June 3 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time)
- Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 1:40 p.m. Pacific Time (4:40 p.m. Eastern Time)
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
- William Blunck Named Chief Operating Officer at Southeast Ventura County YMCA
- 10:00 ET Dr.FORHAIR Offers Best-Selling Folligen Original Shampoo at Special Price Through Leading U.S. Membership Retailer
- Troy Aikman Brings Final Smile to Dying Young Fan
- 07:02 ET 1,838 public high schools in 25 states honored for college readiness, success
- Jeffrey Adams Fitness Introduces New Revolutionary Exercise Training Titled "AWSM Body"
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
Filed Under: Business
0 Comments
Latest on The Californer
- BYD Announces Dealership Agreement with 1 Source Material Handling Inc
- California: Governor Newsom Signs Legislation Strengthening Access to Reproductive Health Care and Protecting Patients & Providers, Lifts Up New Reproductive Freedom Advisory Group
- San Jose: FLASH REPORT #179 - COVID-19 Response and Recovery
- 16:32 ET Beautyforever Hair Brand Day Crazy Deals Are Ready to Surprise
- Atlanta's #1 Food Influencing Brand Launches NFTs for Charity!
- San Francisco: Mayor London Breed Announces Organized Retail Crime Initiative
- San Jose: Public Review Draft IS/ND: Cannabis Business Ordinance Update
- Firefly Reservations Partners with BASYS Processing to Bring Simplified Payment Processing to Easy-to-Use Campground Reservation Management Software
- Breaking Cargo Records at the Port of Long Beach
- Oakland International Film Fest Is Underway Don't Miss Your Ticket To The World Live & Virtual
- 13:00 ET New Documystery Probes, "What if Everything We Think We Know about Jim Morrison is Wrong?"
- Students Start the School Year Strong Thanks to the Summer STARS Program in Sacramento and Yolo C
- CGS3 Expands Partnership with the Addition of Michael Rivera
- Backstretch workers recognized by the first El Mejor Awards to be hosted by Past the Wire
- GSP International Airport integrates a new enterprise operations platform offered by Aerosimple
- Contractors and Passive Income
- 10:05 ET With Market Size Valued at $1.3 Billion by 2026, it's a Healthy Outlook for the Global Beverage Carton Packaging Machinery Market
- California: Governor Newsom Announces Appointments 9.21.21
- 06:35 ET Walker & Dunlop Completes Sale and Financing for Best-in-Class Multifamily Property in LA's Thriving Warner Center
- What should i do if Turkish flight gets canceled